Aduro shows survival benefit with pancreatic cancer vaccine duo

 
• By Alexandra Shimmings

Private US biotech company Aduro BioTech has reported a survival benefit in metastatic pancreatic cancer with its combination immunotherapy-based treatment, in a Phase II trial that was stopped early on the strength of the data after a pre-planned interim analysis.

More from Anticancer

More from Therapy Areas